Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andre Hagevik

Neurology Sun City West, AZ Medical Doctor

NPI 1528039625 CMS profile 23233

14520 W Granite Valley Dr Ste 120, Sun City West, AZ 85375

Open in the dashboard

General payments

$5,601

348 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andre Hagevik of Sun City West, AZ is reported in the CMS Open Payments database as having received $5,601 across 348 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $517 39
2024 General $359 23
2023 General $751 35
2022 General $313 16
2021 General $1,502 95
2020 General $1,102 66
2019 General $1,056 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andre Hagevik
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Andre Hagevik were reported at $517. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Andre Hagevik Neurology median Middle half National median
2019 $1,056 $474 $118–$2,177 $163
2020 $1,102 $367 $82–$2,309 $114
2021 $1,502 $438 $104–$2,547 $132
2022 $313 $442 $103–$2,388 $149
2023 $751 $464 $119–$2,312 $160
2024 $359 $468 $119–$2,323 $164
2025 $517 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,129 80 payments
  2. UCB, Inc. $1,098 72 payments
  3. Teva Pharmaceuticals USA, Inc. $563 31 payments
  4. Amneal Pharmaceuticals LLC $490 29 payments
  5. ACADIA Pharmaceuticals Inc $440 32 payments
  6. Biohaven Pharmaceuticals, Inc. $245 18 payments
  7. SK Life Science, Inc. $181 5 payments
  8. Upsher-Smith Laboratories LLC $173 8 payments
  9. Lilly USA, LLC $170 11 payments
  10. Pfizer Inc. $141 7 payments
  11. Other $973 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,450 337 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $113 6 payments
  3. Education $38 5 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $748 56 payments
  2. Briviact $680 39 payments
  3. QULIPTA $626 42 payments
  4. Neupro $417 33 payments
  5. NUPLAZID $407 30 payments
  6. RYTARY $398 24 payments
  7. AJOVY Central Nervous System $300 15 payments
  8. NURTEC ODT $245 18 payments
  9. Ajovy Central Nervous System $229 14 payments
  10. REYVOW $155 10 payments
  11. Other $2,485 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,884

Median for Neurology: 833

Drug cost

$472,452

Median for Neurology: $202,670

Branded share of claims

20%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 13 $199,017
Emgality Pen Galcanezumab-Gnlm Brand 88 $65,579
Nurtec Odt Rimegepant Sulfate Brand 24 $28,251
Qulipta Atogepant Brand 17 $24,393
Aimovig Autoinjector Erenumab-Aooe Brand 23 $22,406
Ajovy Autoinjector Fremanezumab-Vfrm Brand 19 $19,532
Ubrelvy Ubrogepant Brand 12 $17,880
Neupro Rotigotine Brand 13 $10,400
Gabapentin Generic 404 $9,015
Primidone Generic 240 $7,522

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$90,835

Medicare's payments for the services billed

Medicare patients

436

Average age 77

Services billed

1,055

244 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Chronic kidney disease 38%
Ischemic heart disease 32%
Depression 31%
Diabetes 26%
Osteoporosis 22%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Briviact
  • UCB, Inc. $140
$140 — —
NURTEC ODT
  • PFIZER INC. $40
$40 24 —
ZAVZPRET
  • PFIZER INC. $40
$40 — —
RYTARY
  • Amneal Pharmaceuticals LLC $25
$25 — —
REXULTI
  • Lundbeck LLC $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record